Abstracts tagged "Biomarkers"

Abstract Number: 1191 • ACR Convergence 2024
Discordant Associations Among Chronological and Biological Age with Multi-joint Osteoarthritis and Symptom Burden: The Johnston County Health Study
Liubov Arbeeva¹, Yvonne Golightly², Cameron Kurz³, Matlock Jeffries⁴, Virginia Kraus⁵, Richard Loeser⁶, Duncan Lascelles⁷ and Amanda Nelson³, ¹University of North Carolina, Chapel Hill, Carrboro, NC, ²University of Nebraska Medical Center, Omaha, NE, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Duke University, Durham, NC, ⁶University of North Carolina, Chapel Hill, NC, ⁷North Carolina State University, Raleigh, NC
Background/Purpose: Biological age (BA) may be superior to chronological age (CA) in predicting mortality and age-related conditions such as diabetes and cognitive/functional decline (PMID35715611), as…
Abstract Number: 1463 • ACR Convergence 2024
Investigation of the Cardiometabolic-related Mechanism of Action of Apremilast Through Plasma Proteomics Profiling of Patients with Psoriasis or Psoriatic Arthritis from Three Phase 3 Studies
A. Francesca Setiadi¹, Maggie Burhans², Xuguang Hu², Stephen Colgan³, Kim Notari², Marcia C. Teixeira dos Santos², Apostolos Kontzias², Sue Cheng² and Nehal Mehta⁴, ¹Amgen Inc., South San Francisco, CA, ²Amgen Inc., Thousand Oaks, CA, ³Amgen, Halton Hills, ON, Canada, ⁴The George Washington University School of Medicine, Washington, DC
Background/Purpose: Psoriasis (PsO) and psoriatic arthritis (PsA) are associated with higher rates of obesity and cardiometabolic complications. Apremilast (APR) is an inhibitor of phosphodiesterase 4,…
Abstract Number: 1685 • ACR Convergence 2024
The Renal Activity Index for Lupus (RAIL) Identifies Active Renal Disease in SLE Patients and Its Longitudinal Score Associates with Achievement of Renal Responses in Lupus Nephritis
Minal Aundhia¹, Jinqi Liu², Ellen Cody³, James Rose⁴, Angela Merritt¹, Megan Quinlan-Waters¹, Alyssa Sproles⁵, Sherry Thornton⁵, Prasad Devarajan⁴, Bin Huang⁶ and hermine brunner⁷, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Bristol Myers Squibb, Princeton, NJ, ³Children's Wisconsin, Milwaukee, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵Cincinnati Children's Hospital, Cincinnati, ⁶Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH, ⁷Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: Lupus Nephritis (LN) confers a poor prognosis, and there is a lack of effective non-invasive tests to assess disease activity and treatment response. We…
Abstract Number: 2010 • ACR Convergence 2024
The Influence of Treat-to-target Urate Lowering Therapy and Anti-inflammatory Prophylaxis on Circulating Measures of Inflammation in Gout
Austin Wheeler¹, Tanner Ourada², Michael Duryee¹, Bryant England¹, Richard Reynolds³, James O'Dell¹, Jeff Newcomb¹, Michael Pillinger⁴, Robert Terkeltaub⁵, Ryan Ferguson⁶, Mary Brophy⁶, Tony Merriman⁷ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska-Medical Center: College of Medicine, Omaha, NE, ³University of Alabama at Birmingham, Birmingham, AL, ⁴New York University Grossman School of Medicine, New York,, NY, ⁵Retired, San Diego, CA, ⁶Veterans Affairs, Boston, MA, ⁷University of Alabama at Birmingham, Homewood, AL
Background/Purpose: Gout is the most common inflammatory arthritis worldwide and is associated with substantial cardiometabolic morbidity and mortality. In the STOP Gout trial (O’Dell JR…
Abstract Number: 2267 • ACR Convergence 2024
A Novel Blood-based Assay That Predicts Clinical Response to TNFα Inhibitors or Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis
Maggie Louie¹, Signe Fransen², Katherine Dilger¹, Kevin Lai¹, Diana Abdueva³, David Chernoff⁴ and Jeffrey Curtis⁵, ¹Aqtual Inc, Hayward, CA, ²Aqtual Inc., sf, CA, ³Aqtual Inc., Hayward, CA, ⁴SetPoint Medical, Sausalito, CA, ⁵University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Current rheumatoid arthritis (RA) treatments, including TNFa inhibitors (TNFi) and JAK inhibitors (JAKi), have transformed the management of RA by controlling symptoms and slowing…
Abstract Number: 2434 • ACR Convergence 2024
ESK-001, an Allosteric TYK2 Inhibitor, Maximally Suppresses Type 1 Interferon, a Therapeutic Pathway Central to SLE and CLE
Nicole Narayan¹, Joshua Hoffman², Claire Langrish¹, Sibel Ucpinar³, Pedro Corpuz³, Barbara Mittleman⁴ and Mera Tilley², ¹Alumis, South San Francisco, CA, ²Alumis Inc, South San Francisco, CA, ³Alumis, South San Francisco, ⁴Alumis, Inc., San Francisco, CA
Background/Purpose: ESK-001 is a potent, highly selective, oral, allosteric small molecule inhibitor of TYK2 currently being investigated in adults with active SLE in the LUMUS…
Abstract Number: 2661 • ACR Convergence 2024
Changes in Krebs Von Den Lungen 6 Levels (∆KL6) Predict Fibrosing Progression of Interstitial Lung Disease in Patients with an Underlying Connective Tissue Disease (CTD-ILD)
Fredeswinda Romero-Bueno¹, María Carmen Vegas-Sánchez², lydia Abasolo Alcazar³, Mª Jesus Rodriguez Nieto², Cristina Vadillo-Font⁴, M Asuncion Nieto⁵, Laura Cebrián⁶, Belén López-Muñiz⁶, Jesus Loarce Martos⁷, Juan Rigual⁸, hildegarda Godoy Tundidor⁹, Rosalía Laporta¹⁰, Irene Llorente-Cubas¹¹, Gema Bonilla¹², Luis Gomez Carrera¹³, Rosario García-Vicuña¹⁴, Ana Jaureguizar⁷, Jose Luis Morell Hita⁷, Claudia Valenzuela¹⁵ and Olga Sánchez-Pernaute¹⁶, and the NEREA Study group for Autoimmune ILD, ¹Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain, ²Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, ³IdISSC. HCSC, Madrid, Spain, ⁴Hospital Clinico S Carlos, Madrid, Spain, ⁵Hospital Clínico San Carlos, Madrid, Madrid, Spain, ⁶Hospital Universitario Infanta Leonor, Madrid, Spain, ⁷Hospital Universitario Ramón y Cajal - IRYCIS, Madrid, Spain, ⁸Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ⁹Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Madrid, Spain, ¹⁰Hospital Universitario Puerta de Hierro, Madrid, Spain, ¹¹Hospital Universitario de La Princesa, Madrid, Spain, ¹²H. Universitario La Paz, Madrid, Spain, ¹³Hospital Universitario La Paz, Madrid, Spain, ¹⁴Hospital Universitario de la Princesa, Madrid, Madrid, Spain, ¹⁵Hospital Universitario La Princesa, Madrid, Spain, ¹⁶Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain
Background/Purpose: Krebs von den Lungen-6 (KL6) is a mucin-1 glycoprotein produced by type 2 alveolar epithelial cells , which increase at peripheral blood show a…
Abstract Number: 0056 • ACR Convergence 2024
Association of Soluble Immune Checkpoint Proteins with the Risk of Developing RA in ACPA-positive At-risk Individuals
Ryo Motoyama¹, Shohei Nakamura¹, Eisuke Inoue², Hideto Takada³, Masayoshi Harigai⁴ and Yuko okamoto¹, ¹Tokyo Women's Medical University, Tokyo, Japan, ²Showa University, Tokyo, Japan, ³Tokyo Women's Medical University, Denver, CO, ⁴International University of Health and Welfare, Tokyo, Japan
Background/Purpose: ACPA+ individuals without inflammatory arthritis are considered as being in an at-risk state of RA, although further factors are needed to identify individuals with…
Abstract Number: 0383 • ACR Convergence 2024
Identification of Protein Biomarkers in Tear Fluid of Children with Uveitis That Distinguishes the Ocular Inflammatory State
Ilaria Maccora¹, hermine brunner², Mekibib Altaye³, Alexandra Duell³, Wendy Haffey⁴, Megan Quinlan-Waters³, Alyssa Sproles⁵, Sherry Thornton⁵, Virginia Miraldi Utz³, Kenneth Greis⁴ and sheila Angeles-Han⁶, ¹?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, ²Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Proteomics and Mass Spectrometry, University of Cincinnati, Cincinnati, OH, Cincinnati, OH, ⁵Cincinnati Children's Hospital, Cincinnati, ⁶Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Vision loss occurs in 50% of children with chronic anterior uveitis (CAU). Lack of symptoms and overt ocular signs of inflammation may lead to…
Abstract Number: 0507 • ACR Convergence 2024
Neutrophil Activation Markers Can Predict Rheumatoid Arthritis Treatment Response to the Janus Kinase 1/2 Inhibitor Baricitinib
Runa Kuley¹, Bhargavi Duvvuri¹, Sabeeha Hasnain², Ernst Dow³, Alisa Koch⁴, Richard Higgs⁴, Venkatesh Krishnan⁴ and Christian Lood⁵, ¹University of Washington, Seattle, ²Mahindra University, Hyderabad, India, ³Eli Lilly and Co, Indianapolis, IN, ⁴Eli Lilly, Indianapolis, IN, ⁵University of Washington, Seattle, WA
Background/Purpose: Neutrophils play an important role in regulating immune and inflammatory responses in rheumatoid arthritis (RA). We assessed whether baricitinib, a JAK1/JAK2 inhibitor, could reduce…
Abstract Number: 0658 • ACR Convergence 2024
Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor, Demonstrated Improvements in SLE/LN Disease Measures and Biomarkers in Patients with Highly Active SLE or Nephrotic Range Proteinuria in the Open-label Phase 1b/2 MISSION Study
Richard Furie¹, Amit Saxena², Samir Parikh³, Richard Leff⁴, Lucas Bohnett⁵, Kathryn Ray⁶, Brian Tuch⁴, Janet Anderl⁴, Jennifer Whang⁴ and Kiruthi Palaniswamy⁷, ¹Northwell Health, Manhasset, NY, ²NYU School of Medicine, New York, NY, ³Ohio State University, Columbus, OH, ⁴Kezar Life Sciences, South San Francisco, CA, ⁵Kezar Life Sciences, El Cajon, ⁶Kezar Life Sciences, Mill Valley, CA, ⁷Kezar Life Sciences, Inc, South San Francisco, CA
Background/Purpose: Zetomipzomib is a selective inhibitor of the immunoproteasome with anti-inflammatory and immunomodulatory potential without evidence of immunosuppression to date. The MISSION study (NCT03393013), a…
Abstract Number: 0801 • ACR Convergence 2024
Neutrophil Activation as a Novel Marker of Lung Disease in Rheumatoid Arthritis
Jia Shi¹, Yang Wu¹, Ting Wang², Chen Yu³, qian wang⁴, Xinping Tian⁵, Mengtao Li⁴, Kristen Demoruelle⁶, Joshua Solomon⁷ and Christian Lood², ¹University of Washington, Seattle, ²University of Washington, Seattle, WA, ³Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Dong Cheng Qu, China (People's Republic), ⁴Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China, ⁵Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁶University of Colorado Anschutz Medical Campus, Golden, CO, ⁷National Jewish Health, Denver, CO
Background/Purpose: Neutrophil activation is seen in rheumatoid arthritis (RA), but its involvement in RA interstitial lung disease (RA-ILD) is not clear. Levels of N-formyl methionine…
Abstract Number: 0905 • ACR Convergence 2024
High-Throughput Proteomic Profiling of Sera as a Non-Invasive Method for Identifying Lupus Nephritis Subtypes
Rufei Lu¹, Andrea Fava², Benjamin Jones³, Peter Izmirly⁴, Jennifer Anolik⁵, Chaim Putterman⁶, David Wofsy⁷, Matthias Kretzler⁸, Celine Berthier⁹, E. Steve Woodle¹⁰, Michael Weisman¹¹, Mariko Ishimori¹², The Accelerating medicines Partnership: RA/SLE Network¹³, Betty Diamond¹⁴, Jill Buyon¹⁵, Michelle Petri¹⁶, Richard Furie¹⁷, Judith James¹³ and Joel Guthridge¹³, ¹University of California San Francisco, San Bruno, CA, ²Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, ³Oklahoma State University, Oklahoma City, OK, ⁴New York University Grossman School of Medicine, New York, NY, ⁵University of Rochester Medical Center, Rochester, NY, ⁶Albert Einstein College of Medicine, Safed, Israel, ⁷University of California San Francisco, SF, CA, ⁸University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, ⁹University of Michigan, Ann Arbor, MI, ¹⁰University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cinncinnati, OH, ¹¹Stanford University, Los Angeles, CA, ¹²Cedars-Sinai Health System, Los Angeles, CA, ¹³Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴The Feinstein Institutes for Medical Research, Manhasset, NY, ¹⁵NYU Grossman School of Medicine, New York, NY, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD, ¹⁷Northwell Health, Manhasset, NY
Background/Purpose: Lupus nephritis (LN) treatment decisions are typically informed using histopathological classification based on the International Society of Nephrology/Renal Pathology Society (ISN/RPS) and NIH activity…
Abstract Number: 1202 • ACR Convergence 2024
Harnessing MicroRNA and Machine/Deep Learning for Early Prediction of Knee Osteoarthritis Structural Progression
Afshin Jamshidi¹, Osvaldo Espin-Garcia², Thomas G. Wilson³, Ian Loveless³, Jean-Pierre Pelletier¹, Amanda Ali⁴ and Johanne Martel-Pelletier¹, ¹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ²Department of Epidemiology and Biostatistics, University of Western Ontario; Dalla Lana School of Public Health and Department of Statistical Sciences, University of Toronto; Department of Biostatistics, Schroeder Arthritis Institute; Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Henry Ford Health + Michigan State University Health Sciences, Detroit, MI, ⁴Henry Ford Health + Michigan State University Health Sciences; Center for Molecular Medicine and Genetics, Wayne State University, Montreal, QC, Canada
Background/Purpose: The development of knee osteoarthritis (OA) is generally characterized by a slow evolution. However, its progression and severity may occur rapidly in some individuals.…
Abstract Number: 1488 • ACR Convergence 2024
Clinical Utility and Performance of Anti-C1q Antibodies for Systemic Lupus Erythematosus: Comparative Analysis of Three Different Assays
Mariana Gonzalez-Trevino¹, MeLea Hetrick¹, Alain Sanchez-Rodriguez², Ali Duarte-Garcia¹ and Anne Tebo³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, ³Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
Background/Purpose: SLE is an autoimmune disorder characterized by autoantibody-mediated tissue damage. Antibodies against C1q (anti-C1q) can identify patients with LN and rising titers predict renal…

« Previous Page
1
…
6
7
8
9
10
…
96
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].